Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
98 hedge funds and large institutions have $493M invested in Accelerate Diagnostics in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 18 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 27
17% more capital invested
Capital invested by funds: $422M → $493M (+$70.8M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
10% less funds holding
Funds holding: 109 → 98 (-11)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
60% less call options, than puts
Call options by funds: $2.91M | Put options by funds: $7.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.85M |
| 3 |
MGM
Miura Global Management
New York
|
+$6.4M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.48M |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$5.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$12.4M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$7.15M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
-$4.42M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$2.98M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.85M |
AXDX Hedge Fund Activity: Q1 2017 in Review
98 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2017, worth a combined $493M — up 17% from $422M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of AXDX and 12 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 37 added.
The largest buyer was BlackRock, adding an estimated $33.3M. The largest seller was Newtyn Management, exiting entirely with an estimated $12.4M sold.
- 98 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2017, down from 109 in Q4 2016.
- Funds reported $493M of Accelerate Diagnostics stock for Q1 2017, up 17% quarter-over-quarter.
- 12 funds opened new Accelerate Diagnostics positions in Q1 2017 and 18 closed out, a net change of -6 holders.
- The largest Accelerate Diagnostics buyer in Q1 2017 was BlackRock, an estimated $33.3M added.
- The largest Accelerate Diagnostics seller in Q1 2017 was Newtyn Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2017.